ENTX Stock Price, Chart, Stats & News
Entera Bio Ltd. (ENTX) does not currently pay a dividend.
ENTX chart
Fundamentals
Gross margin | -19.05% |
Operating margin | -20207.14% |
Pretax margin | -20116.67% |
Net margin | -214.29% |
Effective tax rate | – |
ROA | -0.56% |
ROE | -0.55% |
D/E | 0.04x |
Interest coverage ratio | – |
ENTX valuation
P/E | – |
P/S | 1233.78x |
P/B | 3.98x |
P/CF | -2.58x |
P/FCF | -2.55x |
P/OCF | -2.58x |
PEG | -11.15x |
EV multiple | -6.95x |
About
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments.
Similar securities
Based on sector and market capitalization
